{
    "clinical_study": {
        "@rank": "18507", 
        "arm_group": {
            "arm_group_label": "EVP", 
            "arm_group_type": "Experimental", 
            "description": "Subject who use the EVP"
        }, 
        "brief_summary": {
            "textblock": "Electronic Vapour Products (EVPs) is a relatively new class of consumer products that are\n      otherwise known as electronic cigarettes devices/systems. These may look like conventional\n      cigarettes but do not contain tobacco.\n\n      The 'vapour' produced by such devices typically consists of humectants (propylene glycol or\n      glycerol), nicotine, water, and flavours.\n\n      This trial is to evaluate the safety and tolerability of an e-vapour product over two years."
        }, 
        "brief_title": "A Study to Evaluate the Safety of Electronic Vapor Products for 2 Years", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject who participated in the EVP G1 S2 study (S2)\n\n          -  Willingness to use the EVP provided by the sponsor for two years as the only nicotine\n             containing product\n\n          -  No clinically significant abnormalities during the S2 study\n\n        Exclusion Criteria:\n\n          -  Subjects who have used nicotine replacement therapy during the S2 study\n\n          -  Subjects with relevant illness history\n\n          -  Subjects with history of drug or alcohol abuse\n\n          -  Subjects with lung function test or vital signs considered unsuitable Subjects who\n             are trying to stop smoking\n\n          -  Female subjects who are pregnant, or unwilling to use acceptable contraceptive method\n             for the duration of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "420", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143310", 
            "org_study_id": "EVP G1 S3"
        }, 
        "intervention": {
            "arm_group_label": "EVP", 
            "intervention_name": "EVP", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "LS2 9LH"
                    }, 
                    "name": "Covance Clinical Research Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Merthyr Tydfil", 
                        "country": "United Kingdom", 
                        "state": "Wales", 
                        "zip": "CF48 4DR"
                    }, 
                    "name": "Simbec Research"
                }
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-Centre Study to Evaluate the Safety of Use of Electronic Vapour Products for Two Years", 
        "overall_official": {
            "affiliation": "Covance Clinical Research Unit", 
            "last_name": "Jim Bush, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United Kingdom: National Health Service", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline (BL) in blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "BL, 1Month (Mo), 3Mo, 6Mo, 12Mo, 18Mo and end of study (EOS)"
            }, 
            {
                "measure": "Change from BL in electrocardiogram (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "BL, 1Mo, 3Mo, 6Mo, 12Mo, 18Mo and EOS"
            }, 
            {
                "measure": "Change from BL in lung function tests", 
                "safety_issue": "Yes", 
                "time_frame": "BL, 1Mo, 3Mo, 6Mo, 12Mo, 18Mo and EOS"
            }, 
            {
                "measure": "Change from BL in clinical laboratory parameters", 
                "safety_issue": "Yes", 
                "time_frame": "BL, 1Mo, 3Mo, 6Mo, 12Mo, 18Mo and EOS"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143310"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from BL in craving and withdrawal symptoms", 
                "safety_issue": "No", 
                "time_frame": "BL, 1Mo, 2Mo, 3Mo, 6Mo, 9Mo, 12Mo, 15Mo, 18Mo, 21Mo and EOS"
            }, 
            {
                "description": "Nicotine equivalents", 
                "measure": "Change from BL in biomarkers of exposure", 
                "safety_issue": "No", 
                "time_frame": "BL, 1Mo, 2Mo, 3Mo, 6Mo, 9Mo, 12Mo, 15Mo, 18Mo, 21Mo and EOS"
            }, 
            {
                "description": "Hemoglobin, white blood cells", 
                "measure": "Change from BL in biomarkers of effect", 
                "safety_issue": "No", 
                "time_frame": "BL, 1Mo, 2Mo, 3Mo, 6Mo, 9Mo, 12Mo, 15Mo, 18Mo, 21Mo and EOS"
            }
        ], 
        "source": "Fontem Ventures BV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fontem Ventures BV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}